Enterprise Therapeutics–SEVERAL: investment, 202401 financing round Series B follow-on £26m led by Panakès Partners |
2024-01-30 |
Rhineland-Palatinate (govt)–Axa: business park management, 202401– collab of Kadans Science Partner Deutschland + Technologiezentrum Mainz for biotech |
2024-01-29 |
BioLizard–MC Services: public relations, 202401 service existent by MC Services |
2024-01-23 |
Disco Pharmaceuticals–SEVERAL: investment, 202401 seed financing round €20m led by Sofinnova Partners |
2024-01-16 |
Aiolos Bio–GSK: investment, 202401– acquisition $1b upfront + $400m milestones |
2024-01-09 |
Calypso Biotech–Novartis: investment, 202401– acquisition $250m upfront + $175m milestones by Novartis SIGNED |
2024-01-08 |
Full-Life Technologies–OTHER: credit, 202401– loan facility $16m |
2024-01-04 |
Full-Life Technologies–SEVERAL: investment, 202401 financing round Series B $47.3m led by Prosperity7 Ventures + undisclosed healthcare investor |
2024-01-04 |
Elitech–Bruker: investment, 202312– acquisition €870m in cash of Elitech Group from PAI Partners SIGNED Put Option Letter |
2023-12-23 |
Brinter–UPM: bioink, 202312– distribution of GrowInk bioinks of UPM Biomedicals by Brinter in North America + most of Europe + AU+NZ |
2023-12-21 |
Shinobi Therapeutics–EQT: investment, 202312 financing round Series A totalling $51m incl co-lead investor EQT Life Sciences |
2023-12-12 |
Shinobi Therapeutics–SEVERAL: investment, 202312 financing round Series A $51m led by EQT LS + F-Prime Capital + Eight Roads Ventures Japan |
2023-12-12 |
IBA (BE)–Univ Kansas: proton therapy, 202312– colllab research using ConformalFLASH technology on ProteusONE system with KUMC |
2023-12-05 |
Bioxodes–SEVERAL: investment, 202311 financing round Series A €8.6m from existing investors |
2023-11-21 |
Bioxodes–Wallonia (govt): grant, 202311 non-dilutive funding €3.4m from Walloon region |
2023-11-21 |
RED Horticulture–Demeter: investment, 202311 financing round Series A totalling €17m incl existing investor Demeter IM |
2023-11-21 |
RED Horticulture–ECBF: investment, 202311 financing round Series A totalling €17m incl new + lead investor ECBF |
2023-11-21 |
RED Horticulture–SEVERAL: investment, 202311 financing round Series A €17m led by ECBF with Demeter IM + Unigrains |
2023-11-21 |
RED Horticulture–Unigrains: investment, 202311 financing round Series A totalling €17m incl new investor Unigrains |
2023-11-21 |
NMD Pharma–SEVERAL: investment, 202311 financing round Series B €75m led by existing investor Jeito Capital |
2023-11-15 |
Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures |
2023-11-14 |
VectorY–ALS Investment Fund: investment, 202311 financing round Series A totalling €129m incl co-investor ALS Investment Fund |
2023-11-13 |
VectorY–BioGeneration Ventures: investment, 202311 financing round Series A totalling €129m incl existing + co-investor BGV |
2023-11-13 |
VectorY–EQT: investment, 202311 financing round Series A totalling €129m incl new + co-lead investor EQT Life Sciences Dementia Fund |
2023-11-13 |
VectorY–Forbion: investment, 202311 financing round Series A totalling €129m incl existing + co-lead investor Forbion GOF + Forbion Ventures |
2023-11-13 |
VectorY–Insight Partners: investment, 202311 financing round Series A totalling €129m incl co-investor Insight Partners |
2023-11-13 |
VectorY–Merck (US): investment, 202311 financing round Series A totalling €129m incl co-investor MRL Ventures Fund |
2023-11-13 |
VectorY–OTHER: investment, 202311 financing round Series A totalling €129m incl another known investor |
2023-11-13 |
VectorY–SEVERAL: investment, 202311 financing round Series A €129m co-led by EQT Life Sciences + Forbion Growth Opportunities Fund |
2023-11-13 |
ViaNautis Bio–SEVERAL: investment, 202311 financing round Series A $25m led by 4BIO Capital + BGF + UCB Ventures |
2023-11-13 |
ViaNautis Bio–UCB: investment, 202311 financing round Series A totalling $25m incl co-lead investor UCB Ventures |
2023-11-13 |
Kynexis–Forbion: investment, 202311 financing round Series A totalling €57m incl co-founding + lead investor Forbion |
2023-11-07 |
Kynexis–SEVERAL: investment, 202311 financing round Series A €57m led by Forbion |
2023-11-07 |
Kynexis–Sunstone Life Science: investment, 202311 financing round Series A totalling €57m incl co-investor Sunstone Life Science Ventures |
2023-11-07 |
Kynexis–Ysios Capital: investment, 202311 financing round Series A totalling €57m incl co-founding + co-investor Ysios Capital |
2023-11-07 |
Kynexis–Mitsubish Chemical: KAT-II inhibitor, 202311c– license excl ww rights to develop + commercialize KYN-5356 from MTPC |
2023-11-01 |
Aiolos Bio–Forbion: investment, 202310 financing round Series A totalling $245m incl co-lead investor Forbion |
2023-10-25 |
Aiolos Bio–SEVERAL: investment, 202310 financing round Series A $245m co-led by Atlas Venture + Bain + Forbion + Sofinnova Investments with RA Capital |
2023-10-24 |
Agomab Therapeutics–Canaan Partners: investment, 202310 financing round Series C totalling $100m incl new + co-investor Canaan |
2023-10-10 |
Agomab Therapeutics–EQT: investment, 202310 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences |
2023-10-10 |
Agomab Therapeutics–Fidelity: investment, 202310 financing round Series C totalling $100m incl lead investor Fidelity Mgt and Research |
2023-10-10 |
Agomab Therapeutics–KKR: investment, 202310 financing round Series C totalling $100m incl new + co-investor Dawn Biopharma |
2023-10-10 |
Agomab Therapeutics–OTHER: investment, 202310 financing round Series C totalling $100m incl existing investors |
2023-10-10 |
Agomab Therapeutics–SEVERAL: investment, 202310 financing round Series C $100m (€94.9m) led by Fidelity Mgt and Research Company |
2023-10-10 |
AstronauTx–SEVERAL: investment, 202310 financing round Series A £48m led by Novartis Venture Fund |
2023-10-09 |
Gadeta–Clade Therapeutics: investment, 202310 acquisition 100% of Gadeta BV by Clade Therapeutics |
2023-10-02 |
Nagi Bioscience–SEVERAL: investment, 202309 financing round Series A CHF12.4m co-led by Swisscanto + imec.xpand |
2023-09-28 |
Kern Tec–EU (govt): investment, 202309 financing round Series A totalling €12m incl co-investor EIC Fund |
2023-09-27 |
Kern Tec–PeakBridge: investment, 202309 financing round Series A totalling €12m incl co-investor PeakBridge Growth 2 fund |
2023-09-27 |
Kern Tec–SEVERAL: investment, 202309 financing round Series A €12m led by Telos Impact (eventually total includes grants?) |
2023-09-27 |
Kern Tec–Telos Impact: investment, 202309 financing round Series A totalling €12m incl lead investor Telos Impact |
2023-09-27 |
Mainz Biomed–MC Services: public relations, 202309 service existent by MC Services |
2023-09-20 |
Aboleris Pharma–SEVERAL: investment, 202309 financing round Series A €23.7m led by Caixa Capital Risc + co-led by Sound Bioventures |
2023-09-18 |
Broken String Biosciences–Heran Partners: investment, 202309 financing round Series A totalling $15m incl new + co-investor Heran Partners |
2023-09-18 |
Moderna–Immatics: cancer drugs, 202309– strategic r+d collab $120m upfront + >$1.7b funding + milestones + royalties combing tech platforms |
2023-09-11 |
Paptic–SEVERAL: investment, 202309 financing round Series A €23m led by ECBF + incl Ecolab + Itochu Fibre |
2023-09-04 |
Inversago Pharma–Novo Group: investment, 202308– acquisition up to $1.075b in cash by Novo Nordisk A/S |
2023-08-10 |
Aiolos Bio–Hengrui: TSLP-antibody, 202308– acquisition ww excl developm + commercialisation rights to AIO-001 outside of Greater China |
2023-08-01 |
Inversago Pharma–Forbion: investment, 202308 existent shareholder Forbion |
2023-08-01 |
Argenx–SEVERAL: investment, 202307 global offering €979.6m via ADS offering in US + private placement in Europe |
2023-07-17 |
BioGeneration Ventures–BMS: investment, 202307 closing of BGV V totalling €150m incl existing investor BMS |
2023-07-13 |
BioGeneration Ventures–Lilly: investment, 202307 closing of BGV V totalling €150m incl existing investor Eli Lilly |
2023-07-13 |
BioGeneration Ventures–Novo Group: investment, 202307 closing of BGV V totalling €150m incl existing investor Novo Holdings |
2023-07-13 |
BioGeneration Ventures–SEVERAL: investment, 202307 closing of BGV V with €150m incl Lilly + Novo Holdings + BMS et al |
2023-07-13 |
Aphea.Bio–SEVERAL: investment, 202307 financing round Series C €70m led by Innovation Industries |
2023-07-11 |
TolerogenixX–Bruchmann Group: investment, 202307 financing round Series A 2nd closing totalling €7m incl new investor DB Speciality |
2023-07-06 |
TolerogenixX–SEVERAL: investment, 202307 financing round Series A 2nd closing €7m bringing total round to €11.6m |
2023-07-06 |
Rewind Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam |
2023-07-05 |
River BioMedics–SEVERAL: investment, 202307 seed financing round €2m bringing total seed funding to €3.8m |
2023-07-05 |
Versanis Bio–Forbion: investment, 202307 existent shareholder Forbion |
2023-07-01 |
Versanis Bio–Lilly: investment, 202307– acquisition up to $1.925b |
2023-07-01 |
Astraveus–Merck (DE): investment, 202306 seed financing round totalling €16.5m incl co-investor M Ventures |
2023-06-27 |
Astraveus–SEVERAL: investment, 202306 seed financing round €16.5m led by AdBio Partners |
2023-06-27 |
Carthera–EU (govt): investment, 202306 financing round Series B totalling €37.5m incl co-investor EIC Fund |
2023-06-27 |
Carthera–Panakès Partners: investment, 202306 financing round Series B totalling €37.5m incl existing + co-investor Panakès Partners |
2023-06-27 |
Carthera–SEVERAL: investment, 202306 financing round Series B €37.5m led by undisclosed investor |
2023-06-27 |
NLC Ventures–SEVERAL: investment, 202306 1st closing €20m of NCL Health Impact Fund from private investors targeting €100m |
2023-06-26 |
Tagworks Pharmaceuticals–Argot Partners: public relations, 202306 service existent media + investor contact Argot Partners |
2023-06-22 |
Tagworks Pharmaceuticals–Gilde Investment: investment, 202306 financing round Series A totalling $65m incl co-lead investor Gilde Healthcare |
2023-06-22 |
Tagworks Pharmaceuticals–Lightstone Ventures: investment, 202306 financing round Series A totalling $65m incl co-investor Lightstone Ventures |
2023-06-22 |
Tagworks Pharmaceuticals–New Enterprise Associates: investment, 202306 financing round Series A totalling $65m incl co-investor NEA |
2023-06-22 |
Tagworks Pharmaceuticals–Novartis: investment, 202306 financing round Series A totalling $65m incl co-investor Novartis Venture Fund |
2023-06-22 |
Tagworks Pharmaceuticals–SEVERAL: investment, 202306 financing round Series A $65m led by Ysios Capital + Gilde Healthcare |
2023-06-22 |
Tagworks Pharmaceuticals–Ysios Capital: investment, 202306 financing round Series A totalling $65m incl co-lead investor Ysios Capital |
2023-06-22 |
Innovative Health Initiative–EU (govt): grant, 202306– funding €24m for IMAGIO project from IHI |
2023-06-20 |
Innovative Health Initiative–Philips: targeted cancer therapy, 202306– Philips is coordinating partner ot the IMAGIO project of IHI |
2023-06-20 |
Innovative Health Initiative–Thermosome: targeted cancer therapy, 202306– Thermosome is partner in IMAGIO project of IHI |
2023-06-20 |
Thermosome–Innovative Health Initiative: grant, 202306– funding €1.3m as partner in IMAGIO project of IHI |
2023-06-20 |
Danish National Genome Center–Qiagen: genomic software tools, 202306– supply QCI Interpret software for oncology genome sequencing by Qiagen |
2023-06-13 |
Santero Therapeutics–Belgium (govt): investment, 202306 financing round Series A totalling €8m incl co-investor SFPIM |
2023-06-07 |
Santero Therapeutics–Newton Biocapital: investment, 202306 financing round Series A totalling €8m incl lead investor Newton Biocapital |
2023-06-07 |
Santero Therapeutics–OTHER: investment, 202306 financing round Series A totalling €8m incl a group of business angels led by Pierre Drion |
2023-06-07 |
Santero Therapeutics–Sambrinvest: investment, 202306 financing round Series A totalling €8m incl co-investor Sambrinvest |
2023-06-07 |
Santero Therapeutics–SEVERAL: investment, 202306 financing round Series A €8m led by Newton Biocapital |
2023-06-07 |
Santero Therapeutics–Wallonia (govt): investment, 202306 financing round Series A totalling €8m incl co-investor WE Life Sciences |
2023-06-07 |
AAVantgarde Bio–SEVERAL: investment, 202306 financing round Series A €61m led by Atlas Venture + Forbion |
2023-06-06 |
Synaffix–Lonza: investment, 202306 acquisition €100m upfront cash + €60m milestones of Synaffix by Lonza |
2023-06-01 |
Mithra Pharmaceuticals–BioConfidant: public relations, 202305 service existent by Cohesion Bureau |
2023-05-29 |
Michor Consulting–QbD Group: investment, 202305 acquisition of Michor Consulting by QbD Group |
2023-05-25 |
Turnstone Communications–QbD Group: investment, 202305 acquisition of Turnstone Communications by QbD Group |
2023-05-25 |